Q-omics provides the consensus-scored CLDN5 profile across patient tissues and cancer cell-line models. CLDN5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CLDN5 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, CLDN5 RNA expression shows 19,844 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UVM, BLCA, and CCRCC as cancer lineages where CLDN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLDN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLDN5 survival associations across molecular data types. CLDN5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLDN5 RNA expression–survival associations across cancer types. High CLDN5 expression shows unfavorable associations in UVM, LUSC, UCS and KIRP, but favorable associations in KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for CLDN5 RNA expression.
This table summarizes CLDN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CLDN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLDN5 shows lower tumor expression in BLCA, COAD, KICH, THCA, LUAD and KIRP. The BLCA box plot shows higher CLDN5 RNA expression in normal versus tumor tissue (log2 FC = −3.038, t-test p < 0.001).
This table shows molecular features associated with CLDN5 in patient tissues and cancer cell lines. In patient samples, CLDN5 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
